NIH Researchers Discover Mechanism That Could Extend GLP-1 Drug Effects for Addiction Treatment

For the millions of Americans taking GLP-1 receptor agonists like semaglutide, the pattern is familiar: dramatic initial results followed by a frustrating plateau. Now, researchers at the National Institutes of Health have peered inside individual neurons to understand why this happens—and their findings suggest a surprisingly simple biochemical tweak that could extend the drugs' effects for weeks longer than currently possible.

The study, published May 22 in Nature Metabolism, maps the intracellular signaling cascade that makes GLP-1 drugs work. Rather than focusing on which brain regions light up, the NIH team asked what happens within the cells themselves when semaglutide binds to its receptor. What they found challenges assumptions about how these medications function and opens a new frontier for addiction pharmacology.

The cAMP Continuum

At the center of the discovery sits cyclic adenosine monophosphate, or cAMP—a signaling molecule that acts as a cellular messenger. When semaglutide activates GLP-1 receptors in the area postrema, a brainstem region that regulates appetite and nausea, cAMP levels spike. That much was expected.

What surprised researchers was the variation. Using advanced fluorescence imaging in living mouse brain tissue, first author Claire Gao and colleagues observed that cAMP responses fell along a spectrum rather than switching on uniformly. Some neurons sustained elevated cAMP for hours. Others peaked briefly, then faded—possibly because they internalized or degraded their GLP-1 receptors in response to the drug's presence.

"It was not an all or nothing phenomenon," said co-corresponding author Michael Krashes, a senior investigator at NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "We observed that cAMP responses across cells varied on a continuum."

This cellular heterogeneity helps explain a clinical puzzle. Patients on GLP-1 drugs often lose weight rapidly for several months, then stall. The plateau may reflect not just metabolic adaptation but a population of neurons that simply stop responding to each dose because their internal signaling machinery times out early.

Extending the Signal

The NIH team tested whether they could push more neurons into the "sustained response" category. They targeted phosphodiesterase-4 (PDE4), a naturally occurring enzyme that breaks down cAMP. By inhibiting PDE4 with roflumilast—an FDA-approved drug already used for COPD—they demonstrated that neurons could be skewed toward prolonged activation.

The implication is striking: combining GLP-1 drugs with PDE4 inhibitors might extend their therapeutic window, allowing patients to maintain benefits with less frequent dosing. For addiction treatment, where GLP-1s are being investigated for alcohol, opioid, and stimulant use disorders, longer-acting formulations could address one of the field's persistent barriers—medication adherence.

"We know much less about the nuts and bolts of what goes on within the neurons that these medications target," said co-corresponding author Andrew Lutas, an NIDDK investigator. "By digging into these mechanisms, we're beginning to answer some of these questions."

From Appetite to Addiction

The addiction angle is not speculative. The same area postrema neurons that regulate feeding also participate in reward processing and aversion signaling—circuits that are hijacked by addictive substances. GLP-1 drugs have already shown promise in reducing alcohol consumption and cravings in early trials, and 33 clinical trials are now registered testing GLP-1s for substance use disorders.

What makes this study particularly relevant to addiction medicine is its focus on duration of effect. In substance use disorder treatment, maintaining therapeutic drug levels is critical. Patients with opioid use disorder who discontinue buprenorphine face dramatically elevated overdose risk. Alcohol use disorder medications like naltrexone work only when taken consistently. A GLP-1 formulation that maintains efficacy for weeks rather than days could transform the treatment landscape.

The roflumilast connection adds another layer of practicality. Because the drug is already generic and approved, repurposing it as a GLP-1 adjunct could bypass years of regulatory hurdles. Researchers would need to confirm that the mouse findings translate to humans and that PDE4 inhibition doesn't produce unacceptable side effects at the doses required.

Limitations and Next Steps

The study comes with important caveats. The imaging techniques allowed observation over only a matter of hours, not the days or weeks over which GLP-1 drugs are typically administered in patients. The researchers plan to apply newer methods to track intracellular signaling over longer periods.

There is also the question of whether extending cAMP signaling would extend all GLP-1 effects, including the gastrointestinal side effects that cause many patients to discontinue treatment. Nausea and vomiting, mediated partly through the same area postrema circuits, might worsen with PDE4 inhibition—a trade-off that would need careful clinical evaluation.

Still, the study represents a fundamental advance in understanding one of the most widely prescribed drug classes in America. As GLP-1 medications expand from diabetes and obesity into addiction, mental health, and potentially neurodegenerative disease, knowing how to modulate their cellular effects will become increasingly important.

For a field that has spent decades searching for pharmacological tools to address substance use disorders, the idea that a COPD drug and a weight-loss injection might combine to produce longer-lasting recovery support is the kind of unexpected convergence that often drives medical progress. The NIH team's work suggests that convergence may be closer than previously thought.